Amy Pooler - Nov 20, 2023 Form 3 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Role
VP, Head of Research
Signature
Amy Pooler, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
SGMO
Transactions as of
Nov 20, 2023
Transactions value $
$0
Form type
3
Date filed
11/28/2023, 04:14 PM
Next filing
Nov 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SGMO Common Stock 51.5K Nov 20, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGMO Stock Option (Right to Buy) Nov 20, 2023 Common Stock 15K $11.85 Direct F2
holding SGMO Stock Option (Right to Buy) Nov 20, 2023 Common Stock 13.9K $6.80 Direct F3
holding SGMO Stock Option (Right to Buy) Nov 20, 2023 Common Stock 27.5K $11.19 Direct F4
holding SGMO Stock Option (Right to Buy) Nov 20, 2023 Common Stock 27.2K $5.90 Direct F5
holding SGMO Stock Option (Right to Buy) Nov 20, 2023 Common Stock 64.7K $2.66 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (a) 4,584 shares subject to the Reporting Person's February 25, 2021 restricted stock unit ("RSU") grant that will vest in one final installment on February 25, 2024, (b) 8,508 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 21,563 shares subject to the Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration as provided in the 2018 EIP.
F2 Fully vested and exercisable.
F3 One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2020 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F4 One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2021 grant date, and the remainder of the shares subject to the option vest and become exercisable in 36 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F5 One-quarter (1/4) of the shares subject to the option vested and became exercisable on the first anniversary of the February 25, 2022 grant date, and the remainder of the shares subject to the option vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
F6 One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the February 24, 2023 grant date, and the remainder of the shares subject to the option will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.